Webinar Alert! Building Robust Potency Assays with In-Cell Western Assay Protein Expression Readouts Register Today!

Comparative Analysis of ADA Assay Platforms: MSD vs. Gyrolab for Monoclonal Antibody Programs

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Comparative Analysis of ADA Assay Platforms: MSD vs. Gyrolab for Monoclonal Antibody Programs

CELL & GENE | RNA | BIOLOGICS

Frequently Asked Questions (FAQ)

    What is the primary difference between MSD and Gyrolab for ADA assays?

    A: MSD (Meso Scale Discovery) is an electrochemiluminescence (ECL) based planar immunoassay, offering high sensitivity and throughput. Gyrolab is a microfluidic, nanoliter-scale immunoassay platform that excels in minimizing matrix interference and conserving precious sample volume.

    Which platform has better drug tolerance?

    A: Both platforms can be optimized for high drug tolerance. However, the Gyrolab’s affinity capture elution (ACE-Gyrolab) method often provides a distinct advantage in assays for monoclonal antibody programs where high circulating drug concentrations are expected.

    Is one platform more GxP-compliant than the other?

    A: Both MSD and Gyrolab platforms can be fully validated for use in a GxP environment. Compliance is a function of the laboratory’s quality management system, validation protocols, and documentation practices, not the instrument itself. Franklin Biolabs validates all immunogenicity assays to meet global regulatory standards.

    How does sample volume requirement compare?

    A: Gyrolab requires significantly less sample volume (nanoliter scale) compared to MSD (microliter scale). This is a considerable advantage in preclinical studies where sample availability is limited.

A researcher in a lab coat and blue gloves gently holds three white lab mice, symbolizing animal models in scientific research.

Executive Summary

Selecting the appropriate anti-drug antibody (ADA) assay platform is a significant decision in any monoclonal antibody development program. The choice between Meso Scale Discovery (MSD) and Gyrolab platforms directly impacts data quality, drug tolerance, sample consumption, and project timelines. MSD provides high-throughput capacity and sensitivity, while Gyrolab offers superior performance in managing matrix effects and conserving low-volume samples. A data-driven platform selection, tailored to the specific therapeutic modality and study phase, is a requirement for building a robust regulatory submission package.

Strategic Platform Selection

The characterization of unwanted immunogenicity is a core component of every biologic’s safety profile. The platform chosen to detect and quantify ADAs must be sensitive, specific, and resistant to interference from both the drug product and endogenous matrix components. An incorrect platform choice can lead to ambiguous data, delaying program progression and complicating regulatory interactions.

A digital rendering of a DNA double helix on a dark blue background with floating particles.

A stylized, 3D rendering of a DNA double helix in light blue and white, set against a soft-focus, light gray background.

MSD and Gyrolab: A Comparative Technical Analysis

A direct comparison reveals distinct operational advantages for each platform. The optimal choice depends entirely on the specific context of the monoclonal antibody program and the nature of the samples being analyzed.

Parameter Meso Scale Discovery (MSD) Gyrolab
Core Technology Planar Electrochemiluminescence (ECL) Microfluidic Nanoliter-scale Immunoassay
Sensitivity High (typically low ng/mL) High (typically low ng/mL)
Drug Tolerance Good; can be improved with acid dissociation Excellent; particularly with ACE-Gyrolab methods
Matrix Effects Moderate; requires careful buffer optimization Minimal; flow-through design reduces interference
Sample Volume 25-50 µL per well 2-4 µL per data point
Throughput High (96- and 384-well plates) High (automated, runs up to 112 data points)
Ideal Use Case High-volume screening, studies with ample sample Volume-sparing studies, complex matrices, high drug concentrations

Implications for Monoclonal Antibody Program Timelines

The principle of selecting the right analytical tool for a specific biological question is well-established. Foundational research comparing different viral vector serotypes (PMID: 17343566) or the performance of various reporter proteins (PMID: 17510373) demonstrates that empirical, comparative data is necessary to optimize outcomes. This same logic applies directly to bioanalytical platform selection.

Making the correct platform choice upfront provides the specific bioanalytical data needed to avoid costly assay redevelopment. A well-characterized assay, established on the right platform, supports an efficient path toward regulatory filing, aligning with our typical 18-24 month IND timeline.

A marketing flyer for Franklin Biolabs detailing their immunogenicity services, including various assays and support for cell and gene therapy clinical trials.

Franklin Biolabs’ GxP-Compliant Platform Expertise

At our >100,000 sq ft GxP-compliant facility, our bioanalytical teams possess deep expertise in developing and validating ADA assays on both MSD and Gyrolab platforms. We guide our partners through a phase-appropriate strategy, ensuring the selected methodology generates unambiguous data for confident decision-making. This rigorous, science-first approach was central to the 100% IND success rate achieved since 2019 by the core scientific team that now constitutes Franklin Biolabs. The Franklin Biolabs brand, launched in 2024, continues this long-standing legacy of scientific and regulatory excellence.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities